EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Therapeutic targeting of bleomycin‐induced pulmonary fibrosis by human bone marrow mesenchymal stem cell‐derived extracellular vesicles and/or pirfenidone: Impact of sex in mature adult mice

Jennie S Charoenphannathon, Simon G Royce, Yasmin Higham, Jane E Bourke iD, Chrishan S Samuel iD

British Journal of Pharmacology · 2026-09 · 183 (18) · 5423-5439

DOI: 10.1111/bph.70539 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Pharmacology, online erschienen am 17.06.2026. Verfasst von Jennie S Charoenphannathon und 4 weiteren Autor:innen. Beteiligte Einrichtung: Cardiovascular Disease Program, Monash Biomedicine Discovery Institute and Department of Pharmacology, Monash University, Clayton, Victoria, Australi…. Hauptthemen laut MEDLINE: Pyridones, Mesenchymal Stem Cells, Extracellular Vesicles, Pulmonary Fibrosis. Die Arbeit nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Monash University, Monash Biomedicine Discovery Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Purpose Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease with limited therapeutic options. This study compared the therapeutic effects of bone marrow mesenchymal stem cell‐derived extracellular vesicles (BM‐MSC‐EVs) with an IPF treatment, pirfenidone (PFD), in mature adult mice with established pulmonary fibrosis. Experimental Approach Nine to 10‐month old male and female C57BL/6 mice received an intranasal instillation of bleomycin (BLM) or saline on Days 0 and 7. Sub‐groups of BLM‐injured mice (n = 10 per group) were left untreated until Day 21 (d21) or d28 post‐injury, or received an intranasal administration of BM‐MSC‐EVs (d21), once‐daily oral PFD treatment (d21 to d27), or both treatments combined. Measures of lung compliance, inflammation and fibrosis were assessed at d28. Key Results BLM‐injured male and female mice had increased lung inflammation and interstitial transforming growth factor (TGF‐ β 1), myofibroblast and extracellular matrix (ECM) accumulation, but reduced matrix metalloproteinase (MMP 9) activity and MMP9:TIMP‐1 ratios at d21. These end‐points were maintained at d28 in male mice but were resolved in female mice. BM‐MSC‐EVs alone or combined with PFD attenuated or significantly reduced the lung inflammation and fibrosis‐related end‐points in male mice and promoted lung MMP‐9 activity in both sexes. In comparison, PFD alone partially but significantly reduced fibrosis progression but did not affect MMP or TIMP levels. Conclusions and Implications BM‐MSC‐EVs exerted anti‐fibrotic effects in male mice, which were maintained with PFD co‐administration. Treatment outcomes remained inconclusive in female mice. These findings highlight how ageing and sex influence therapeutic responses of EV‐based therapies for IPF.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PyridonesMesenchymal Stem CellsExtracellular VesiclesPulmonary FibrosisAnimalsFemaleMaleBleomycinMice, Inbred C57BLHumansMiceSex FactorsMatrix Metalloproteinase 9Lung

Stichwörter der Autor:innen

BM‐MSC‐EVageingcombination therapypirfenidonepulmonary fibrosissex

Substanzen

pirfenidoneBleomycinPyridonesMatrix Metalloproteinase 9

Autor:innen und Institutionen

  • Cardiovascular Disease Program, Monash Biomedicine Discovery Institute and Department of Pharmacology, Monash University, Clayton, Victoria, Australia.

ORCID-Profile: Jane E Bourke, Chrishan S Samuel

Förderung

  • Monash University
  • Monash Biomedicine Discovery Institute

Zitieren

APA

Charoenphannathon, J. S., Royce, S. G., Higham, Y., Bourke, J. E., & Samuel, C. S. (2026). Therapeutic targeting of bleomycin‐induced pulmonary fibrosis by human bone marrow mesenchymal stem cell‐derived extracellular vesicles and/or pirfenidone: Impact of sex in mature adult mice. British Journal of Pharmacology, 183(18), 5423-5439. https://doi.org/10.1111/bph.70539

Vancouver

Charoenphannathon JS, Royce SG, Higham Y, Bourke JE, Samuel CS. Therapeutic targeting of bleomycin‐induced pulmonary fibrosis by human bone marrow mesenchymal stem cell‐derived extracellular vesicles and/or pirfenidone: Impact of sex in mature adult mice. British Journal of Pharmacology. 2026;183(18):5423-5439. doi:10.1111/bph.70539

BibTeX
@article{Charoenphannathon2026,
  author = {Charoenphannathon, Jennie S and Royce, Simon G and Higham, Yasmin and Bourke, Jane E and Samuel, Chrishan S},
  title = {Therapeutic targeting of bleomycin‐induced pulmonary fibrosis by human bone marrow mesenchymal stem cell‐derived extracellular vesicles and/or pirfenidone: Impact of sex in mature adult mice},
  journal = {British Journal of Pharmacology},
  year = {2026},
  volume = {183},
  number = {18},
  pages = {5423--5439},
  doi = {10.1111/bph.70539}
}
Kostenlos starten →